Sequencing CAR T-Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Dr. Binod Dhakal leads a discussion on the increasingly complex treatment landscape of relapsed/refractory multiple myeloma (RRMM), focusing on how clinicians navigate sequencing decisions among BCMA-directed therapies, including CAR T-cell therapy and bispecific antibodies.

Dr. Carol Ann Huff emphasizes that treatment selection is highly individualized and depends on factors such as disease aggressiveness, prior therapies, remission duration, treatment eligibility, and regulatory considerations.

She notes that while BCMA-targeted approaches have demonstrated significant clinical benefit, not every patient requires immediate escalation to these therapies.

Dr. Prerna Mewawalla further highlights the importance of disease kinetics, patient fitness, logistical considerations, access to treatment centers, and patient preferences when deciding between CAR T-cell therapy and bispecific antibodies.

The panel underscores the value of shared decision-making and comprehensive patient assessment, illustrating how clinical, logistical, and personal factors collectively influence sequencing strategies in the evolving RRMM treatment landscape.